
CLAIMS

1. A pharmaceutical composition comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate (Formula I)



Formula I

and one or more bases, wherein the one or more bases is a solid.

2. The pharmaceutical composition of claim 1, wherein the composition comprises 0.1 mg to 2 g of Formula I.

3. The pharmaceutical composition of claims 1 or 2, wherein upon dissolution of the composition in an aqueous solution the composition has a pH between 7 and 10.5.

4. The pharmaceutical composition of any one of claims 1-3, wherein a conjugate acid of the one or more bases has a pKa between 6 and 11.

5. The pharmaceutical composition of any one of claims 1-4, wherein the one or more bases are one or more of:

a) a C_{1-8}-alkyl mono-, di-, or tri- carboxylic acid salt,
b) a phosphate salt,
c) an amine and/or a salt thereof,
d) an acetate salt,
e) a hydroxide and/or alkoxide salt,
f) a carbonate and/or bicarbonate salt, and/or
g) a borate salt.

6. The pharmaceutical composition of any one of claims 1-5, wherein the composition comprises 10 to 1500 mg of the one or more bases.

7. The pharmaceutical composition of any one of claims 1-6, wherein the one or bases are an amine and/or a salt thereof, optionally wherein the one or more bases are H_2NR^{20}, $HNR^{20}R^{21}$, $NR^{20}R^{21}R^{22}$, and/or a salt thereof wherein each R^{20}, R^{21}, and R^{22} are independently C_{1-8} alkyl optionally substituted with one or more −OH, optionally wherein the one or more bases are tris(hydroxymethyl)aminomethane, meglumine, and/or a tris(hydroxymethyl)aminomethane salt.

8. The pharmaceutical composition of any one of claims 1-6, wherein the one or more bases are an alkali carbonate and/or sodium phosphate, optionally wherein the sodium phosphate is Na_2HPO_4.

9. The pharmaceutical composition of any one of claims 1-8, wherein the molar ratio of Formula I to the one or more bases is at least 1:2.


10. The pharmaceutical composition of any one of claims 1-9, wherein Formula I and the one or more bases are milled together, optionally wherein the composition is suitable for constitution, or reconstitution if lyophilized, with an aqueous solution into a pharmaceutically acceptable liquid, optionally wherein the composition is admixed with an aqueous solution, optionally wherein the aqueous solution is sterile water for injection or 0.9% sodium chloride injection, optionally wherein the composition is admixed with 0.5 to 500 mL of an aqueous solution.

11. The pharmaceutical composition of any one of claims 1-10, wherein the composition is for injection, optionally wherein the composition is for injection intravenously.

12. The pharmaceutical composition of any one of claims 1-11, wherein the composition comprises one or more of mannitol, lactose, sucrose, trehalose, sorbitol, glucose, raffinose, arginine, glycine, histidine, dextran, polyvinylpyrrolidone, polyethylene glycol, polypropylene glycol, a lactate salt, polysorbate 80, and ethylene diamine tetraacetic acid (EDTA) or a salt thereof.

13. The pharmaceutical composition of any one of claims 1-12, wherein the composition has < 5% N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide after one week at room temperature.


14. A salt solution comprising water and a salt formed from Formula I




Formula I

and an amine and/or salt thereof, wherein the salt solution is for injection.


15. The salt solution of claim 14, wherein the salt solution comprises $(HO)_nR^8NH_3^+$, $[(HO)_nR^8]_2NH_2^+$, or $[(HO)_nR^8]_3NH^+$, wherein each R^8 is independently C_{1-8}alkyl and n is 0 or C_{1-8}-alkylene and each n is independently 1-8, optionally wherein the salt solution comprises



and/or



16. The salt solution of claims 14 or 15, wherein the salt solution comprises at least a 1:2 molar ratio of Formula III




Formula III

to the protonated amine.

17. The salt solution of any one of claims 14-16, wherein the salt solution comprises a sterile solution, optionally wherein the salt solution comprises 0.5 to 500 mL of the sterile solution, optionally wherein the sterile solution is sterile water for injection or 0.9% sodium chloride injection, optionally wherein the salt solution is for injection intravenously.

18. The salt solution of any one of claims 14-17, wherein the pH of the salt solution is between pH 7 and pH 10.5.


19. A method for making the salt solution of any one of claims 14-18 comprising admixing Formula I



Formula I

and an amine and/or a salt thereof, in an aqueous solution.

20. A kit comprising Formula I



Formula I

and one or more bases.

21. The kit of claim 20, wherein a conjugate acid of the one or more bases has a pKa between 6 and 11.

22. The kit of claims 20 or 21, wherein the one or more bases are one or more of:

a) a C_{1-8}-alkyl mono-, di-, or tri- carboxylic acid salt,

b) a phosphate salt,

c) an amine and/or a salt thereof,

d) an acetate salt,

e) a hydroxide and/or alkoxide salt,

f) a carbonate and/or bicarbonate salt, and/or

g) a borate salt.

23. The kit of any one of claims 20-22, wherein the one or bases are an amine and/or a salt thereof.

24. The kit of any one of claims 20-23, wherein the one or more bases are H_2NR^{20}, $HNR^{20}R^{21}$, $NR^{20}R^{21}R^{22}$, and/or a salt thereof wherein each R^{20}, R^{21}, and R^{22} are independently C_{1-8} alkyl optionally substituted with one or more –OH.

25. The kit of any one of claims 20-24, wherein the one or more bases are tris(hydroxymethyl)aminomethane, meglumine, and/or a tris(hydroxymethyl)aminomethane salt.

26. The kit of any one of claims 20-23, wherein the one or more bases are an alkali carbonate and/or sodium phosphate.

27. The kit of claim 26, wherein the sodium phosphate is Na_2HPO_4.

28. The kit of any one of claims 20-27, wherein Formula I and the one or more bases are in the same container or in one or more different containers.

29. The kit of any one of claims 20-28, wherein the kit further comprises a sterile solution.

30. The kit of claim 29, wherein the sterile solution is sterile water for injection or 0.9% sodium chloride injection.

31. The kit of claims 29 or 30, wherein the sterile solution comprises the one or more bases.

32. The kit of any one of claims 20-31, wherein the kit comprises instructions for administering Formula I to a patient in need thereof.

33. The pharmaceutical composition of any one of claims 1-13, the salt solution of any one of claims 14-18, or the kit of any one of claims 20-32 for use in treating or controlling a disease or condition mediated by an aquaporin, wherein the pharmaceutical composition, salt solution, or kit is to be administered to a patient in need thereof.

34. The pharmaceutical composition, salt solution or kit of claim 33, wherein the disease or condition is edema.

35. The pharmaceutical composition, salt solution or kit of claim 34, wherein the disease or condition is cytotoxic cerebral edema.

36. Use of the pharmaceutical composition of any one of claims 1-13, the salt solution of any one of claims 14-18, or the kit of any one of claims 20-32 in the manufacture of a medicament for treating or controlling a disease or condition mediated by an aquaporin.

37. The use of claim 36, wherein the disease or condition is edema.

38. The use of claim 37, wherein the disease or condition is cytotoxic cerebral edema.